The majority of mesothelioma patients (50–75%) harbor genetic alterations in Hippo pathway regulatory components, including NF2 loss of function mutation/deletion and LATS1-PSEN1 fusion/LATS2 deletion, which lead to YAP activation and Hippo pathway gene expression Bueno et al., 2016. The gene discussed is LATS2; the disease is mesothelioma.